Ford Motor Company vs McKesson Corporation — how do they compare? Ford Motor Company trades at $12.3 (market cap $48.33B), while McKesson Corporation trades at $930 (market cap $106.14B). The key difference: McKesson Corporation is far larger — about 2.2× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.95%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and McKesson Corporation for 74 Days on average.
| F | MCK | |
|---|---|---|
Market Cap | $48.33B | $106.14B |
Volume | 33,572,159 | 794,405 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $995.69 |
52-Week Low | $11.21 | $725.17 |
Typical Hold Time | 104 Days | 74 Days |
Enterprise Value | $180.29B | $112.67B |
Dividend Yield | 4.95% | 0.41% |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% with a bearish technical outlook. The company reported mixed quarterly results, beating Q1 and Q2 2026 EPS estimates but missing Q4 2025. Recent news highlights a 6.6% Q3 sales decline due to model phase-outs and supplier issues affecting F-150 production. Cash flow improved in 2025 with $560M net inflow, but profitability remains challenged with negative net income margin of -3.93% and ROE of -18.31%.
Ford faces headwinds from declining sales and profitability challenges, though analyst consensus remains cautiously optimistic with a $15.90 price target. The stock offers value with low P/S (0.26) and P/E (11.21) ratios, but investors must weigh competitive pressures and execution risks against potential turnaround opportunities in hybrid vehicle adoption and commercial divisions.
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →